Candel Therapeutics (CADL) analyst forecast and price target
Analyst forecast
Consensus of 9 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| B of A Securities | Upgraded | Neutral → Buy | $18.00 from $12.00 | Sep 21, 2026 |
| B of A Securities | Maintained | Neutral | $12.00 from $9.00 | Aug 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 | Aug 13, 2026 |
| Stifel | Initiated Coverage | Buy | $22.00 | Jul 13, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Apr 20, 2026 |
| Citigroup | Maintained | Buy | $26.00 from $22.00 | Mar 18, 2026 |
| Canaccord Genuity | Maintained | Buy | $25.00 | Mar 13, 2026 |
| Citigroup | Maintained | Buy | $22.00 from $24.00 | Mar 13, 2026 |
| Stephens & Co. | Maintained | Overweight | $15.00 | Dec 8, 2025 |
| Citigroup | Maintained | Buy | $24.00 from $25.00 | Nov 14, 2025 |
| Stephens & Co. | Initiated Coverage | Overweight | $15.00 | Oct 28, 2025 |
| LifeSci Capital | Initiated Coverage | Outperform | $16.00 | Oct 21, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 | Sep 29, 2025 |
| B of A Securities | Downgraded | Buy → Neutral | $7.00 from $13.00 | Sep 3, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $23.00 | Jun 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $19.00 | Apr 11, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $19.00 | Mar 14, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $19.00 | Feb 26, 2025 |
| Canaccord Genuity | Maintained | Buy | $25.00 from $20.00 | Feb 26, 2025 |
| Citigroup | Initiated Coverage | Buy | $25.00 | Feb 20, 2025 |
Frequently asked questions
Is CADL a buy, sell, or hold?
Analysts covering Candel Therapeutics currently average a Buy rating: 9 buy, 0 hold and 0 sell, from 9 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CADL?
On Sep 21, 2026, B of A Securities upgraded Candel Therapeutics to Buy with a price target of $18.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.